Neratinib compound

A technology of neratinib and its compounds, which is applied in the field of neratinib compounds and their preparation, can solve problems such as poor method reproducibility, high impurity content, content and crystal form cannot be reproduced, and achieve good stability and high The effect of purity

Inactive Publication Date: 2018-03-09
TIANJIN HANKANG PHARMA BIOTECH
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] There are multiple preparation methods for neratinib, among which the preparation method of neratinib is disclosed in U.S. Patent No. 7,399,865, but no matter what method, the purity of nerat

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Neratinib compound
  • Neratinib compound
  • Neratinib compound

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] In a 50L reactor, add 3 kg of neratinib (purity 97.3%, HPLC) and 30.3 L of water-acetone-ammonia=9:0.8:1.1 mixture, heat to 88°C-91°C, add 150 gram of activated carbon, insulated and stirred for 30 minutes, filtered while hot, and the filtrate was naturally cooled to room temperature under stirring, and then incubated for 5.5 hours, crystallization was precipitated, filtered, and vacuum-dried at room temperature to obtain 2.81 kilograms of neratinib crystals. Melting point: 198.5°C-199.6°C, purity 99.95%, single impurity 0.04%, MS: 349.13 (M+H) solvent residue detection meets the requirements.

[0031] The X-ray instrument model and measurement conditions of the crystal: Rigaku D / max 2500 diffractometer; CuKa 40Kv100mA; 2θ scanning range: 0-50 ° .

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the technical field of medicine, and specifically relates to neratinib and a preparation method thereof. The new crystal form of neratinib obtained in the invention has the advantages of high purity, the largest impurity is less than 0.5‰, good stability, and heavy method. The reproducibility is good, and the purity and crystal form can be well reproduced when it is scaled up to the pilot scale.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a neratinib compound and a preparation method thereof. Background technique [0002] Neratinib (neratinib, HKI-272) is an oral irreversible pan-ErbB receptor tyrosine kinase inhibitor that is currently undergoing phase III clinical trials worldwide by Pfizer, which can effectively inhibit ErbB1 and ErbB2 tyrosine Kinase activity, the mechanism of its action is to inhibit the ATP sites of EGFR (ErbB-1) and HER2 (ErbB-2) in cells to prevent phosphorylation and activation of tumor cells, through EGFR (ErbB-1) and HER2 (ErbB-2) ) homogeneous and heterogeneous dimers block the down-regulation signal, so as to achieve the purpose of tumor control. For patients with ErbB-2-positive advanced breast cancer, oral neratinib has shown good clinical effects. [0003] The structural formula of neratinib is as follows: [0004] [0005] Chemical name: (2E)-N-[4-[[3-chloropyri...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D401/12A61K31/4709A61P35/00
CPCC07D401/12C07B2200/13
Inventor 严洁王志凤
Owner TIANJIN HANKANG PHARMA BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap